Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents. 1993

L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens 30602.

In order to study the structure-activity relationships of L-oxathiolanyl nucleosides as potential anti-HIV agents, a series of enantiomerically pure L-oxathiolanyl pyrimidine and purine nucleosides were synthesized and evaluated for anti-HIV-1 activity in human peripheral blood mononuclear (PBM) cells. The key intermediate 8 was synthesized starting from L-gulose via 1,6-thioanhydro-L-gulopyranose. The acetate 8 was condensed with thymine, 5-substituted uracils and cytosines, 6-chloropurine, and 6-chloro-2-fluoropurine to give pyrimidine and purine nucleosides. Upon evaluation of these final nucleosides, the 5-fluorocytosine derivative 51 was found to be the most potent compound among those tested. In the case of 5-substituted cytosine analogues, the antiviral potency was found to be in the following decreasing order: cytosine (beta-isomer) > 5-iodocytosine (beta-isomer) > 5-fluorocytosine (alpha-isomer) > 5-methylcytosine (alpha-isomer) > 5-methylcytosine (beta-isomer) > 5-bromocytosine (beta-isomer) > 5-chlorocytosine (beta-isomer). Among the thymine, uracil, and 5-substituted uracil derivatives, thymine (alpha-isomer) and uracil (beta-isomer) derivatives exhibited moderate anti-HIV activity. In the purine series, the antiviral potency is found to be in the following decreasing order: adenine (beta-isomer) > 6-chloropurine (beta-isomer) > 6-chloropurine (alpha-isomer) > 2-NH2-6-Cl-purine (beta-isomer) > guanine (beta-isomer) > N6-methyladenine (alpha-isomer) > N6-methyladenine (beta-isomer). The cytotoxicity was also determined in human PBM cells as well as Vero cells. None of the synthesized nucleosides was toxic up to 100 microM in PBM cells.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D011741 Pyrimidine Nucleosides Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. Nucleosides, Pyrimidine
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013876 Thiophenes A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur. Thiophene

Related Publications

L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
July 2008, Archives of pharmacal research,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
December 2004, Bioorganic & medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
March 2000, Nucleosides, nucleotides & nucleic acids,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
June 2019, Bioorganic & medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
October 1988, Journal of medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
March 1994, Journal of medicinal chemistry,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
November 2011, Bioorganic & medicinal chemistry letters,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
September 2007, Antiviral research,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
June 2007, Bioorganic & medicinal chemistry letters,
L S Jeong, and R F Schinazi, and J W Beach, and H O Kim, and S Nampalli, and K Shanmuganathan, and A J Alves, and A McMillan, and C K Chu, and R Mathis
September 2012, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!